International Clinical Trial: Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115485) titled 'Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma' on Aug. 4.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai Henlius Biotech

Condition: Gastric or Gastroesophageal Junction Adenocarcinoma

Intervention: Drug: HLX43 DOSE 1 Drug: HLX43 DOSE 2

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 20, 2025

Targe...